Institutional investors deployed capital across several sectors during the first half of 2025, with hedge funds such as Armistice Capital and large holders including Vanguard Group, BlackRock, Morgan Stanley, and JPMorgan Chase all appearing in the shareholder filings of companies spanning quick-service restaurants, software development, and biotechnology. Three of those companies reported notable results in the quarters that followed.
Restaurant Brands International, the parent of Burger King, Tim Hortons, and Popeyes, pushed forward with international expansion. GitLab grew enterprise revenue as its AI development tools moved into public beta. Rigel Pharmaceuticals posted sales gains above 50% for every drug in its commercial lineup.
What Attracted Institutional Interest in Restaurant Brands International?
Third-quarter 2025 revenue for Restaurant Brands came in at $2.45 billion, topping Wall Street’s $2.40 billion estimate. Comparable sales rose 4.0% globally, led by 6.5% growth across international locations. Tim Hortons extended its streak of positive same-store sales to 18 quarters.
CPE, a Chinese alternative asset manager overseeing roughly $22 billion, committed $350 million in November 2025 to operate Burger King’s China business and expand it from about 1,250 restaurants to more than 4,000 over the next decade.
“China remains one of the most exciting long-term opportunities for Burger King globally,” said Joshua Kobza, CEO of Restaurant Brands International. “CPE is a well-capitalized, proven operator with exceptional leadership and extensive consumer and restaurant experience, making them an ideal partner to fuel the next chapter of Burger King China’s growth.”
Hedge funds such as Armistice Capital, alongside holders including Vanguard Group, Royal Bank of Canada, and Pershing Square Capital Management, acquired Restaurant Brands shares during Q2 2025. Institutions own about 82.3% of outstanding shares. The company carried a market capitalization of nearly $23.45 billion as of early January 2026.
Why Did Funds Take Positions in GitLab?
GitLab posted Q3 fiscal 2026 revenue of $244.4 million, 25% above the prior-year period. Customers paying $100,000 or more annually increased at the same pace. Non-GAAP operating margin expanded to 18%.
The Duo Agent Platform, which entered public beta in July 2025, lets multiple AI agents divide up development work so that a developer can hand off code writing, security checks, and context gathering as parallel tasks rather than handling each one sequentially. The approach separates GitLab from single-assistant tools like GitHub Copilot and Cursor.
“More code means more of a need for GitLab,” said Bill Staples, CEO at GitLab. “Engagement is growing across our platform as we are a critical part of how our customers deliver high-quality, secure software.”
Armistice Capital, ARK Investment Management, and William Blair Investment Management were among the hedge funds that took positions in GitLab during 2025. Vanguard Group holds 8.14%, BlackRock owns 6.84%, and JPMorgan Chase accounts for 4.29%. Institutions collectively control about 95% of outstanding shares. GitLab’s market capitalization sat at roughly $6.1 billion as of early January 2026.
What Is Happening at Rigel Pharmaceuticals?
Rigel’s Q3 2025 net product sales reached $64.1 million, 65% higher than the year-ago quarter. TAVALISSE, its chronic immune thrombocytopenia drug, accounted for $44.7 million, with 70% growth leading the portfolio. GAVRETO and REZLIDHIA contributed $11.1 million and $8.3 million, respectively, and each grew by at least 50%.
Raul Rodriguez, Rigel’s president and CEO, stated the “strong third-quarter performance demonstrates our strategic focus on commercial execution, pipeline development, and financial discipline.”
Rigel presented Phase 1b data for R289, an oral compound targeting interleukin receptor-associated kinases 1 and 4, at the American Society of Hematology Annual Meeting in late 2025. Among heavily pretreated patients with lower-risk myelodysplastic syndromes, roughly one-third of those on higher doses achieved transfusion independence for more than eight weeks. Rigel raised its full-year 2025 revenue guidance to $285 million to $290 million and expects positive net income for the year.
Grifols, Kissei Pharmaceutical, and other partners license international rights to some of Rigel’s approved drugs and contribute collaboration revenue. Hedge funds such as Armistice Capital, alongside BlackRock and Morgan Stanley, own shares in Rigel. Jefferies upgraded the stock to Buy from Hold following the Q3 report.
Comments are closed.